Série pharmaceutique d'amélioration de sexe de matières premières Flibanserin pour le gain de muscle 167933-07-5
Abstrait
CAS:167933-07-5
MF:C20H21F3N4O
MW:390.4
EINECS:1806241-263-5
température de stockage. 2-8°C
solubility DMSO: soluble10mg/mL, clear
color white to beige
Hazard statements H301-H315-H319-H335
Precautionary statements P261-P301+P310-P305+P351+P338
Hazard Codes T
Risk Statements 25-36/37/38
Safety Statements 26-45
La description
Flibanserin is used for hypoactive sexual desire disorder among women. Those receiving flibanserin report a 0.5 increase compared to placebo in the number of times they had “satisfying sexual events”.In those on flibanserin it rose from 2.8 à 4.5 times a month while women receiving placebo reported also an increase of “satisfying sexual events” from 2.7 à 3.7 times a month.The onset of the flibanserin effect was seen from the first timepoint measured after 4 weeks of treatment and maintained throughout the treatment period.
The effectiveness of flibanserin was evaluated in three phase 3 clinical trials. Each of the three trials had two co-primary endpoints, one for satisfying sexual events (SSEs) and the other for sexual desire. Each of the 3 trials also had a secondary endpoint that measured distress related to sexual desire.
Application
Flibanserin is used for hypoactive sexual desire disorder among women. Those receiving flibanserin report a 0.5 increase compared to placebo in the number of times they had “satisfying sexual events”. In those on flibanserin it rose from 2.8 à 4.5 times a month while women receiving placebo reported also an increase of “satisfying sexual events” from 2.7 à 3.7 times a month.The onset of the flibanserin effect was seen from the first timepoint measured after 4 weeks of treatment and maintained throughout the treatment period.
certificat d'authenticité
| Testing Items |
Caractéristiques |
Résultats |
| Caractéristiques |
An off-white to white powder |
Complied |
| Identification |
Meet the requirements |
Positif |
| Perte au séchage |
≤0.50% |
0.13% |
| Métaux lourds |
≤20PPM |
<20PPM |
| Pureté (par CLHP) |
99.0% |
99.2% |
| Conclusion: |
The commodity is complied with the standard of the factory |
1. Hot sales
| Acétate de testostérone |
Acétate de trenbolone |
T-A001 MGF 2mg |
| Cypionate de testostérone |
Trenbolone Énanthate |
T-A002 PEG MGF 2mg |
| Décanoate de testostérone |
Acétate de boldénone |
T-A003 CJC-1295 with DAC 2mg |
| Énanthate de testostérone |
Undécylénate de boldénone |
T-A004 CJC-1295withoutDAC 2mg |
| Isocaproate de testostérone |
Cypionate de boldénone |
T-A005 PT-141 10mg |
| Phénylpropionate de testostérone |
Propionate de boldénone |
T-A006 MT-1 10mg |
| Propionate de testostérone |
Décanoate de nandrolone |
T-A007 MT-2 10mg |
| Undécanoate de testostérone |
Phénylpropionate de nandrolone |
T-A008 GHRP-2 5mg |
| Mestérone |
Undécylate de nandrolone |
T-A009 GHRP-6 5mg |
| Testostérone Sustanon 250 |
Cypionate de nandrolone |
T-A009 GHRP-6 10mg |
| Acétate de clostébol |
Propionate de nandrolone |
T-A010 Ipamorelin 2mg |
| Méthylandrostanolone |
Méthyltriénolone |
T-A011 Hexarelin 2mg |
| Énanthate de méthénolone |
Propionate de drostanolone |
T-A012 Sermorelin 2mg |
| Acétate de méthénolone |
Énanthate de drostanolone |
T-A013 Oxytocin 2mg |
| Anadrol |
Stanolone |
T-A014 TB500 2mg |
| Anavar |
Tadalafil |
T-A015 pentadecapeptide BPC 157 2mg |
| Winstrol |
Vardénafil |
T-A016 GH 176-191 2mg |
| Citrate de clomifène |
Dianabol |
T-A017 Triptorelin 2mg |
| Citrate de torémifène |
Citrate de Tamoxifène |
T-A018 Tesamorelin 2mg |
| Finastéride |
chlorhydrate |
T-A020 Gonadorelin 2mg |
| T-A022 Selank 5mg |
T-A021 DSIP 2mg |
T-A020 Gonadorelin 10mg |
Directeur commercial